{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:18:30Z","timestamp":1788383910042,"version":"build-2803163510"},"reference-count":55,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>\n                    Pediatric B-cell acute lymphoblastic leukemia (B-ALL) has been the poster child of progressive success in the development of leukemia therapy. Among the genomically defined high-risk subtypes of B-ALL are those with\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -rearrangement (r) which are associated with inferior outcomes with chemotherapy-based approaches.\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r ALL is most common in the infantile period but can be seen beyond it and has remained a therapeutic challenge. Recent clinical trials have shown a significant improvement in response rates and survival outcomes in infantile and pediatric non-infant patients with\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r B-ALL when treated with blinatumomab-containing regimens. A single course of sequential blinatumomab added to Interfant-06 chemotherapy led to an exceptional improvement in 2-year disease free survival to 82% compared to 49% from historical chemotherapy only approach. In the salvage settings the use of tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy has led to high response rates and durable remissions in pediatric\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r B-ALL. Recently, inotuzumab ozogamicin was approved in pediatric (&gt;1 year) relapsed\/refractory B-ALL, widening immunotherapy-based salvage options. However, the efficacy of inotuzumab in\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r B-ALL remains questionable, given lower CD22 expression in this ALL genotype. Additionally, the approval of menin inhibitors like revumenib in\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r pediatric acute leukemias provides another treatment option in the salvage setting for this high-risk pediatric B-ALL subtype. These targeted agents are positively altering the treatment approaches and outcomes in pediatric\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r B-ALL, and the use of better residual disease monitoring with next generation sequencing might further help to refine treatment approaches in such high-risk pediatric ALL.\n                  <\/jats:p>","DOI":"10.46989\/001c.141198","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T15:21:31Z","timestamp":1751037691000},"source":"Crossref","is-referenced-by-count":2,"title":["Moving the Needle in KMT2A Rearranged Pediatric B-Cell Acute Lymphoblastic Leukemia: Newer agents and novel approaches"],"prefix":"10.46989","volume":"7","author":[{"given":"Anwesha","family":"Ray","sequence":"first","affiliation":[{"name":"Lady Hardinge Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Jain","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zj0ps89","id-type":"ROR","asserted-by":"publisher"}],"name":"Dept. of Haematology, Safdarjung Hospital, Vardhaman Mahavir Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Vijayaran","sequence":"additional","affiliation":[{"name":"Dept. of Clinical Haematology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Thomas","sequence":"additional","affiliation":[{"name":"Dept. of Haematology, Sri Ramachandra Medical College, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[{"name":"Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukul","family":"Aggarwal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dwcqs71","id-type":"ROR","asserted-by":"publisher"}],"name":"Dept. of Haematology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"9321","key":"ref1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(02)08782-2","article-title":"Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region","volume":"359","author":"C. H. Pui","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"ref2","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"G. C. Issa","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"ref3","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/blood-2013-03-486647","article-title":"Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells","volume":"122","author":"B. E. Li","year":"2013","journal-title":"Blood"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"G. C. Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"20","key":"ref5","doi-asserted-by":"publisher","first-page":"e70326","DOI":"10.1002\/cam4.70326","article-title":"Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia","volume":"13","author":"L. Yin","year":"2024","journal-title":"Cancer Med"},{"issue":"17","key":"ref6","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia","volume":"388","author":"I. Mvd. Sluis","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"M. S. Topp","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"9","key":"ref8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"H. Kantarjian","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"ref9","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome\u2013Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"G. Martinelli","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"ref10","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"N. G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"C. Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"36","key":"ref12","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"34","author":"Av. Stackelberg","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"ref13","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse","volume":"41","author":"L. E. Hogan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"F. Locatelli","year":"2021","journal-title":"Jama"},{"issue":"9","key":"ref15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"P. A. Brown","year":"2021","journal-title":"Jama"},{"issue":"8","key":"ref16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.23.01392","article-title":"Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL","volume":"42","author":"A. Hodder","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"ref17","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2023-189648","article-title":"Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial","volume":"142","author":"S. M. Luger","year":"2023","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2025.2449582","article-title":"Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy","author":"J. Senapati","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"ref19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","volume":"392","author":"S. Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"9583","key":"ref20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"R. Pieters","year":"2007","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"100204","DOI":"10.1016\/j.ejcped.2024.100204","article-title":"KMT2A-rearranged acute lymphoblastic leukaemia","volume":"4","author":"R. S. Kotecha","year":"2024","journal-title":"EJC Paediatric Oncology"},{"issue":"25","key":"ref22","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study","volume":"37","author":"R. Pieters","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3324\/haematol.2021.280146","article-title":"Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial","volume":"107","author":"E. M. Guest","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"ref24","doi-asserted-by":"publisher","first-page":"e30204","DOI":"10.1002\/pbc.30204","article-title":"Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol","volume":"70","author":"A. Popov","year":"2023","journal-title":"Pediatric Blood & Cancer"},{"issue":"6","key":"ref25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/JCO.20.02333","article-title":"Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol","volume":"39","author":"J. Stutterheim","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref26","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia","volume":"388","author":"I. M. van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"ref27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2023-181379","article-title":"Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and\/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy","volume":"142","author":"J. Senapati","year":"2023","journal-title":"Blood"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41408-024-01179-4","article-title":"Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab","volume":"14","author":"E. J. Jabbour","year":"2024","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"ref29","first-page":"293","article-title":"Myeloid lineage switch in KMT2A- rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies","volume":"109","author":"A. Bataller","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"ref30","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2352-3026(22)00258-7","article-title":"CD19 CAR T cells for infants and young children","volume":"9","author":"H. Shalabi","year":"2022","journal-title":"The Lancet Haematology"},{"issue":"5","key":"ref31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"S. L. Maude","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"ref32","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"T. W. Laetsch","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"ref33","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.22.02120","article-title":"Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A<\/i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-M\u00fcnster Study Group","volume":"41","author":"R. E. v. Weelderen","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"ref34","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"A. B. Leahy","year":"2022","journal-title":"Blood"},{"issue":"10","key":"ref35","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"S. Ghorashian","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012638","article-title":"Feasibility and Favorable Responses Following Investigational CAR T-Cell Therapy for Relapsed and Refractory Infant ALL","author":"C. Annesley","year":"2024","journal-title":"Blood Advances"},{"issue":"14","key":"ref37","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"A. Moskop","year":"2022","journal-title":"Blood Advances"},{"issue":"1","key":"ref38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia","volume":"3","author":"M. A. Pulsipher","year":"2022","journal-title":"Blood Cancer Discovery"},{"issue":"9","key":"ref39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"M. M. O'Brien","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"ref40","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"N. N. Shah","year":"2015","journal-title":"Pediatric Blood & Cancer"},{"issue":"10","key":"ref41","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","article-title":"Inotuzumab Ozogamicin for Relapsed\/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22","volume":"27","author":"H. M. Kantarjian","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"ref42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.23901","article-title":"Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody","volume":"90","author":"E. Jabbour","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"1","key":"ref43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41408-024-01098-4","article-title":"Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin","volume":"14","author":"J. Senapati","year":"2024","journal-title":"Blood Cancer Journal"},{"issue":"9","key":"ref44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"G. C. Issa","year":"2021","journal-title":"Blood Cancer Journal"},{"key":"ref45","article-title":"Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial","author":"S. Pharmaceuticals","year":"2025","journal-title":"Syndax Pharmaceuticals"},{"issue":"6","key":"ref46","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","article-title":"Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts","volume":"9","author":"N. J. Short","year":"2025","journal-title":"Blood Advances"},{"issue":"2","key":"ref47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/leu.2014.172","article-title":"Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia","volume":"29","author":"K. Koh","year":"2015","journal-title":"Leukemia"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"100200","DOI":"10.1016\/j.ejcped.2024.100200","article-title":"New insights into hematopoietic cell transplantation in ALL: Who should be transplanted, when, and how","volume":"4","author":"D. Tomizawa","year":"2024","journal-title":"EJC Paediatric Oncology"},{"issue":"19","key":"ref49","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1182\/bloodadvances.2020004157","article-title":"Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene\u2013rearranged acute lymphoblastic leukemia","volume":"5","author":"T. Takachi","year":"2021","journal-title":"Blood Advances"},{"issue":"13","key":"ref50","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"N. J. Short","year":"2022","journal-title":"Blood Advances"},{"issue":"7","key":"ref51","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1200\/JCO.22.01297","article-title":"Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23\/<i>KMT2A<\/i> Rearrangements in a Modern Therapy Era: A Retrospective International Study","volume":"41","author":"A. Attarbaschi","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"ref52","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"S. W. Brady","year":"2022","journal-title":"Nature Genetics"},{"issue":"1","key":"ref53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1999.17.1.191","article-title":"Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation","volume":"17","author":"J. E. Rubnitz","year":"1999","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref54","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","article-title":"Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community","volume":"38","author":"B. Cuglievan","year":"2024","journal-title":"Leukemia"},{"issue":"20","key":"ref55","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"R. Gardner","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/141198-moving-the-needle-in-kmt2a-rearranged-pediatric-b-cell-acute-lymphoblastic-leukemia-newer-agents-and-novel-approaches","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:46:51Z","timestamp":1788382011000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/141198-moving-the-needle-in-kmt2a-rearranged-pediatric-b-cell-acute-lymphoblastic-leukemia-newer-agents-and-novel-approaches"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.141198","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}